{"name":"Genexine, Inc.","slug":"genexine-inc","ticker":"","exchange":"","domain":"genexine.com","description":"","hq":"Seongnam-si","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"GX-188E","genericName":"GX-188E","slug":"gx-188e","indication":"Other","status":"phase_2"},{"name":"Gx-G6","genericName":"Gx-G6","slug":"gx-g6","indication":"Other","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"GX-I7","genericName":"GX-I7","slug":"gx-i7","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"NESP","genericName":"NESP","slug":"nesp","indication":"Chronic kidney disease-related anemia","status":"phase_3"}]}],"pipeline":[{"name":"GX-188E","genericName":"GX-188E","slug":"gx-188e","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"GX-I7","genericName":"GX-I7","slug":"gx-i7","phase":"phase_2","mechanism":"GX-I7 is a recombinant human fibroblast growth factor 21 (FGF21) protein.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Gx-G6","genericName":"Gx-G6","slug":"gx-g6","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NESP","genericName":"NESP","slug":"nesp","phase":"phase_3","mechanism":"NESP is a recombinant human erythropoietin analog that stimulates erythropoiesis.","indications":["Chronic kidney disease-related anemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFA4ZlpwZFFmdnc4aUJoeVhjR0lEWENxMTZuSWd2OG9iZWpVWDctS0ZabWRFUlcweTdzRE9IWHhwQzJEQVVtSE1yUnV3TjVpTklpVlk2bkRMWkJWVVYxZ2ZQdld5OTloaGtVTDZLU3daOA?oc=5","date":"2025-10-27","type":"pipeline","source":"Straits Research","summary":"Erythropoietin Drugs Market Size, Share, Players & Trends by 2034 - Straits Research","headline":"Erythropoietin Drugs Market Size, Share, Players & Trends by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOVzE5VHptbEVTRk9FOGpEWGh3M0hEM3BVbDhHd3NkOEMtU3RtNW9PcE1nbHZiQ1dSUno5cTRabXlkcUxNYUR4dDNvcGJVMi1vNlhaTE9WZ3NtcnVmOXp4SFdsVTN5aWZvQXlseVZ0blZJSlFCdXlMQzMtMnFLc2ltd09oWDMxb0gtZFBNRU9ER1pPYXlnZTFSUXNRWTVMV3EtbUlj?oc=5","date":"2025-03-11","type":"deal","source":"BioWorld News","summary":"MASH field still hot as Boehringer axes $870M deal with Yuhan - BioWorld News","headline":"MASH field still hot as Boehringer axes $870M deal with Yuhan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE13QVlCTExDUUVGdWNQLVNvbVFvVndXbm9sQ2lfMEFDeTdRUXpDckpEU1JQQ1kyUUp5MnZJT0NKLW5IaVlZWWNwNkhCcVB0dmFNNWdha2ZZVnZUV3FyajU3cHRUc0lURHlfc1FFYUx30gFyQVVfeXFMTTZsanU5VENOalBqY0VEX205S3RYdHo0U2otNFdTYWZLNy1rbWNoR09NRVBHM3lhS3JwOHJZNHZHcHlCeFZuell3bEdWZG9RaUczRGtlUDV1RkZnSURtNDkzZFFSd094ODVXRTdSM2FFaXhB?oc=5","date":"2025-03-07","type":"pipeline","source":"koreabiomed.com","summary":"Boehringer Ingelheim terminates steatohepatitis drug development, returns rights to Yuhan - koreabiomed.com","headline":"Boehringer Ingelheim terminates steatohepatitis drug development, returns rights to Yuhan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1pQWNWQ29xNmw0d08ta3FiSjd3VlAyZ2ZrX2xtOVp5NThRcENyem0yRjZ1TmlIM1AtNzBDNFpGcl9zVk5neHRldm9TaVUwczI4cTJsbkQ5RmZKSnFHalBNSzd3MWVlMUVzazRuMk1B0gFyQVVfeXFMUE5KcEJrT2hNMDFlUmV4Z1phQk93aFphY0w3Ny1pTks0Y2V3S0tTUkU1OTEyQlhFbXp6U1NKZWVjTGVtTi1tS20tUFlocHEwSFRjZ0JhTDBxbHlfcWVJTUUwbEtRWWYwREJnQWdwc19ndXJn?oc=5","date":"2025-02-27","type":"trial","source":"koreabiomed.com","summary":"Genexine’s brain cancer drug flops in trial as cash reserves shrink, licensing deals falter - koreabiomed.com","headline":"Genexine’s brain cancer drug flops in trial as cash reserves shrink, licensing deals falter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNSnlhd2pndUMxdVpsT1RKYkVPQllzcXJNZmg3YVFlVXUtNGsxbFMyQm1PRWxwNjR0V2Uyalp6SG1xQmJEd3RkdE9uYzlzbmVySXVhdmhPd2JaNDdFTC1SbWJiNTJHTTJMMEF5UmZqcTVMOVh3YkxWaEJ4dm96X0pXOTc5Zk9HVmtBXzJtaXA4Z2xSU2I4aDY2d01pTUM0djNMY2ZxTWpzbERsTDFEV201TFRYVEN6b0UzUDhXeDJ3Rnk2TDkzN24wWlpLVmRhV1RaeHRPcUJtd1NVb2FLTUdLWg?oc=5","date":"2024-07-04","type":"deal","source":"businesswire.com","summary":"Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline - businesswire.com","headline":"Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9xMFdNdzJDYkx3d091dTh1dmk2bjlKQnZ4QVQwb0J4N1UxZ0lDbmJHdk0tS3JzNTNJMXMzaDBBd2FYQXl2UjlCRk5tZGZ5QWdxRDh4UmdnMjBSbDBlSVcybQ?oc=5","date":"2023-09-12","type":"deal","source":"复宏汉霖","summary":"Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA-Media - 复宏汉霖","headline":"Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFB6ZDh2Rkg0LWpfSUNFa1FockZva1lYYW9fTDFvQlU5SlFxaTJRazdWQnh5MDV4Z1FINDlWZ3ZFekZBLWFKc3ZQb1FSYnItZ2NYUFF0dzc5SmVvR0lMeDdTaU93alJCc190dl9MQ2t30gFyQVVfeXFMTVprbGstbVRlUjNRQm9fWVZRSFlBc3Z3emJYbHlmaE0zcXlrUUFPbHozcXh0WkFkUTVjNlRwenBwZVZrLVNYN3ZrRktTcm5FTmxtZ3VJOEV6LTVoNEd2dnVhZURMY09qQlZhdzFaOHM4UURB?oc=5","date":"2022-03-14","type":"pipeline","source":"koreabiomed.com","summary":"Genexine to give up Covid-19 vaccine development - koreabiomed.com","headline":"Genexine to give up Covid-19 vaccine development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNaW5NUG5OaTdVQ0hzMWJaVWptQlVDV3VKeHl0YVJBT1E2SjlBMzU2Nm1GZWFLZF9Hd01xNy1ZdGdXelVYeWxaVURtUkdRTllvY0NmU0U2M2hVRllwbk8wMkJNc1RpclJWU0xXcEJOeTAtaGZCR0k3aFo5NXpGbHNTb18zeHRpVUhkYmd6RWI0WHFzM091NGhILXFlemRPV2dOdnlPSERYbVp2ZzF0ZkJ6eWl0ZXk1b1BaZzY0OHJ3?oc=5","date":"2020-12-02","type":"pipeline","source":"Reuters","summary":"North Korea-linked hackers targeted J&J, Novavax in hunt for COVID research - Reuters","headline":"North Korea-linked hackers targeted J&J, Novavax in hunt for COVID research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1SSFhQdkhfWVpzQ1AzQU9ZQXIyOUVLMDJOcURnTWRrc3FzNzVvVW40eEc4dmpmbWlkdjZTcXdCeG13YkMwY05LTDY3UE1TV0dQWWVBT2tXOUs3am12?oc=5","date":"2019-09-25","type":"pipeline","source":"nationthailand.com","summary":"BGIC, Korean giant join for development of Thai bio-pharmaceutical industry - nationthailand.com","headline":"BGIC, Korean giant join for development of Thai bio-pharmaceutical industry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFBzTTFabW1JUmY2bWJlN0JsUDlKWEdnZTZHUk5vdDR4UHA4M2ZzNi0tMjY5UElvZnYwNmpOVkU3UkVWWkcxZFlsZ1pwTFhWQ2VOUTctTmhNYTFuZw?oc=5","date":"2019-01-08","type":"pipeline","source":"Yonhap News Agency","summary":"Handok Pharmaceutical, Genexine purchase U.S. bio firm - Yonhap News Agency","headline":"Handok Pharmaceutical, Genexine purchase U.S. bio firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQX2pKSVpIdDQ5a0otY1ZWdlV2ZzlZUDRMLUJ4cUFoSkFCRENRZDRzVlJSRTU1dFlxNnM0bWR1cVlwWnpQSFlXbzJwZFBSUGtVSWZfMHAtcWtHRmc2Umg1bUwzWnFoUl90SHBxelJMaUgtTjktZWtFV1RseHVMSmtVaF9PSVJhY1hBc3NV?oc=5","date":"2018-11-10","type":"pipeline","source":"Tempo.co English","summary":"Kalbe Farma Inaugurates New Biological Drug Factory - Tempo.co English","headline":"Kalbe Farma Inaugurates New Biological Drug Factory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPOGRkM01xenFfaHYtdWNfbkpZYnc2b2lzaE53M01LMjJScXJVWXNzLThpbkRGY0M3cHQ4UFVfRHcwa0h4eFVFb2t2VzV5dmlkNkFwaDZlcGVmZC1uOHRIQUQ0TkZZd3dBbG5KSDhQcmo0WXJOSFJMeFBSekdFTkpPMXZHZTdWQmR2S0k0X1MyekYybVNacmNzSFV3?oc=5","date":"2016-11-16","type":"pipeline","source":"Fierce Pharma","summary":"Merck pairs PD-1 powerhouse Keytruda with Genexine vax to fight HPV-based cancers - Fierce Pharma","headline":"Merck pairs PD-1 powerhouse Keytruda with Genexine vax to fight HPV-based cancers","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":3,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}